Dynamic Technology Lab Private Ltd Buys Shares of 13,717 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Dynamic Technology Lab Private Ltd bought a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 13,717 shares of the company's stock, valued at approximately $439,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alpha DNA Investment Management LLC purchased a new position in shares of SpringWorks Therapeutics during the third quarter valued at $411,000. Charles Schwab Investment Management Inc. increased its holdings in shares of SpringWorks Therapeutics by 13.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 602,227 shares of the company's stock valued at $19,295,000 after purchasing an additional 73,613 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of SpringWorks Therapeutics by 20.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 643,192 shares of the company's stock worth $20,608,000 after purchasing an additional 108,109 shares in the last quarter. Intech Investment Management LLC purchased a new position in SpringWorks Therapeutics during the third quarter valued at approximately $676,000. Finally, Commerce Bank purchased a new position in SpringWorks Therapeutics during the third quarter valued at approximately $207,000.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX traded down $0.25 on Friday, hitting $41.48. 645,350 shares of the stock were exchanged, compared to its average volume of 1,001,843. The company has a market capitalization of $3.09 billion, a PE ratio of -10.69 and a beta of 0.79. The business's fifty day moving average is $33.19 and its 200 day moving average is $36.74. SpringWorks Therapeutics, Inc. has a 52 week low of $28.00 and a 52 week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.03. The firm had revenue of $49.10 million during the quarter, compared to analysts' expectations of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company's revenue for the quarter was up 4810.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.27) earnings per share. Analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SWTX has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an "overweight" rating in a report on Wednesday, September 4th. Evercore ISI initiated coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an "outperform" rating and a $60.00 target price on the stock. HC Wainwright lowered their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a "buy" rating on the stock in a report on Tuesday, November 12th. Finally, Wedbush restated an "outperform" rating and set a $77.00 target price on shares of SpringWorks Therapeutics in a report on Monday, November 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $69.50.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.